Laurus Labs Q2 Review: Brokerages Split As Jefferies Raises Target, Two Retain Sell
Jefferies and Goldman Sachs rate stocks including Laurus Labs.
· NDTV Profit
Laurus Labs more than doubled its Q2 net profit as revenue rose 33.5% and EBITDA surged 86.3%. Jefferies raised its target price to Rs 2,100, while Kotak and Goldman Sachs retained Sell ratings, citing valuation concerns despite improving growth prospects.
The analysis
Earnings versus expectations is what actually re-rates a stock; the surprise matters more than the absolute number.
Market context
- Brokerage calls from Jefferies and Goldman Sachs, with ratings on the stocks named. The stocks: Laurus Labs.
- Over three months: Laurus Labs +26.0% against Pharma & Healthcare -2.1% (28.1 points ahead).
| Company | Price | Day | 1M | 3M | From 52-wk high | Volume vs 20-day | Market cap |
|---|---|---|---|---|---|---|---|
| Laurus LabsLAURUSLABS · Pharma & Healthcare | ₹2,328.40 | +3.8% | +13.4% | +26.0% | +3.8% | 1.3× | — |
Pharma & Healthcare
1M -3.2% · 3M -2.1%
Laurus Labs
Prices as of 30 Oct 2026, 09:43 IST. Sector moves are the average of the stocks we track in each sector.
In this story
Related coverage
India's pharma, healthcare deal volumes rise 23% in Q3 2026: Report
Syngene International shares surge 12%, biggest 1-day gain in 6 years; what drove the rally despite a Q2 profit drop?
Cipla Q2 Results: Profit falls 35% YoY to Rs 878 crore, revenue slips 2%
Stocks To Watch Today: IndiGo, Suzlon Energy, Trent, Coal India, Meesho Among Others
Godrej Consumer Q2: Net Profit Up 14%, Rs 5 Interim Dividend Declared